BioLife Solutions (NASDAQ:BLFS) Insider Karen Foster Sells 511 Shares

Key Points

• Insider Karen Foster sold 511 shares of BioLife Solutions for a total of $13,710.13, representing a 0.26% decrease in their holdings.
• BioLife Solutions reported a loss of ($0.33) EPS for the last quarter, missing analysts' estimates, but the company had revenues of $25.42 million compared to expectations of $23.71 million.
• Equities analysts have issued various ratings on BioLife Solutions, with an average rating of "Buy" and price targets ranging up to $32.00.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Karen Foster sold 511 shares of the firm's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $26.83, for a total value of $13,710.13. Following the transaction, the insider owned 193,672 shares in the company, valued at approximately $5,196,219.76. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

BioLife Solutions Price Performance

BioLife Solutions stock traded up $0.29 during mid-day trading on Monday, reaching $25.80. 403,794 shares of the company were exchanged, compared to its average volume of 478,382. The company has a fifty day simple moving average of $23.47 and a 200-day simple moving average of $23.29. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.55. The firm has a market cap of $1.24 billion, a PE ratio of -214.98 and a beta of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The company had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BLFS. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions during the 4th quarter worth about $31,000. State of Wyoming lifted its stake in shares of BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 1,490 shares during the period. US Bancorp DE boosted its position in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,528 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock valued at $83,000 after purchasing an additional 441 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after purchasing an additional 663 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on BLFS shares. Zacks Research upgraded BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. Stephens started coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Wall Street Zen lowered BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $31.29.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.